Multiply Labs, a San Francisco-based company developing robotic systems for pharmaceutical manufacturing, has raised $75 million in Series B financing, bringing its total funding to more than $100 million. The round was led by Dr. Patrick Soon-Shiong of NantWorks, with participation from AstraZeneca, Lingotto, Teradyne, Strange Ventures, and several existing investors.
The funding will support the expansion of Multiply Labs' robotic manufacturing platform, which automates manual processes involved in producing cell and gene therapies and other biologic medicines. The company intends to increase manufacturing capacity, enhance its technology, and expand its engineering, regulatory, and commercial teams as it progresses toward commercial-scale operations.
Initially developed for cell and gene therapy manufacturing, the platform is being extended to support additional biologic modalities, including antibodies, viral vectors, and messenger RNA (mRNA) therapies. Its robotic systems are designed to operate alongside existing manufacturing instruments, allowing pharmaceutical and biotechnology companies to deploy and manage the technology within their own facilities.
The approach aims to address manufacturing constraints associated with increasingly complex therapies, particularly as advances in artificial intelligence accelerate drug discovery and development.
"AI is designing more therapies than the industry will ever be able to manufacture," said Fred Parietti, cofounder and CEO of Multiply Labs.
"This funding lets us build the capacity to close that gap so more of the patients who need these treatments can actually get them."
Founded in 2016, Multiply Labs initially focused on automated production of personalized dietary supplements and pharmaceutical capsules before transitioning into advanced therapy manufacturing. The company previously raised $20 million in Series A financing in 2021.
In 2024, Multiply Labs entered a commercial and supply agreement with biotechnology company Retro Biosciences, valued at up to $85 million, to automate manufacturing processes for cell therapies targeting age-related diseases.
The company operates within a growing market for automated cell therapy manufacturing, alongside competitors such as Cellares, which provides integrated manufacturing and quality-control systems.
Multiply Labs' latest financing reflects continued investment in manufacturing automation as biotechnology companies seek to improve production capacity, operational efficiency, and access to advanced therapies.
Click here for the original news story.
